化学冷光免疫检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、样品类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球化学冷光免疫检测(CLIA) 市场预计将从 2025 年的 126.3 亿美元成长到 2031 年的 169.4 亿美元，复合年增长率为 5.02%。

化学冷光免疫检测(CLIA) 是一种重要的诊断技术，它利用化学反应产生光，从而能够对临床检体中的抗原和抗体进行精确定量。此市场成长的主要驱动力是全球慢性病和感染疾病病率的上升，这反过来又增加了检查室对精确、高通量检测的需求。 MedTech Europe 2024 的估计值显示欧洲医疗技术市场价值约为 1,700 亿欧元，其中体外诊断占最大份额。

然而，自动化分析仪平台所需的大量资本投入阻碍了市场扩张。这些仪器的高昂购买成本，加上试剂的持续成本以及对专业人员的需求，对资源匮乏地区的小规模医疗机构和检查室构成了巨大的经济障碍。因此，这些经济限制因素可能成为阻碍这项先进诊断技术广泛应用的主要因素。

市场驱动因素

全球慢性病和感染疾病负担日益加重，是推动全球化学冷光免疫检测市场发展的主要动力。与传统方法相比，CLIA 具有更高的灵敏度和更宽的检测范围，因此临床检查室越来越依赖 CLIA。在肿瘤学领域，准确的生物标记检测对于早期诊断至关重要。根据美国癌症协会发布的《2025 年癌症事实与数据》，预计到 2025 年，美国将新增 2,041,910 例癌症病例，将对免疫检测检测产生巨大的需求。同样，高灵敏度的诊断工具在感染疾病管理中也至关重要，因为早期发现是改善患者预后的关键，这进一步巩固了该技术在医疗保健领域的作用。

同时，自动化、高通量化学发光免疫分析（CLIA）平台的技术进步正在解决现代实验室的营运难题，加速市场成长。诊断中心正从手动ELISA方法转向全自动系统，以满足不断增长的检测量，同时缩短处理时间并减少误差。这一趋势在行业财务数据中也得到了体现。罗氏2024年年度报告预测，在免疫诊断需求的推动下，其诊断业务销售额将达到143亿瑞士法郎。此外，雅培于2025年1月发布的「2024年第四季及全年业绩」报告预测，不计新冠肺炎疫情，其全球诊断业务销售额将成长4.3%，凸显了核心诊断技术的持续应用。

市场挑战

自动化化学冷光免疫检测(CLIA) 分析仪需要大量的资金投入，这严重限制了市场成长。资源匮乏地区的小规模实验室和医疗机构往往缺乏资金来承担此类精密设备的高昂初始投资成本。此外，持续的营运成本，例如专用试剂和维护费用，也进一步加重了本就捉襟见肘的预算。因此，许多机构仍然依赖低成本的检测方法，例如酶联免疫吸附试验 (ELISA)，这限制了 CLIA 技术的广泛应用，并直接阻碍了市场扩张。

这些资金限制也清楚地反映在产业的支出模式中，揭示了诊断领域资源的匮乏。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，体外诊断支出将约占医疗保健总支出的0.6%。这项数据表明，与医疗保健总支出相比，诊断领域的资金分配明显偏低。资金分配的不足限制了检查室的购买力，使得购买昂贵的自动化CLIA平台对很大一部分潜在基本客群在经济上难以负担。

市场趋势

新型生物标记在早期检测领域的应用日益广泛，从根本上重塑了市场格局，促使临床检查室从常规检测转向高附加价值的专业检测。这一趋势包括快速采用先进的化学冷光检测法来诊断自体免疫疾病、内分泌失调和潜伏性行为感染等复杂病症，这些技术相比传统方法具有更高的特异性。製造商正积极将这些小众生物标记添加到其检测项目中，以确保更高的报销率和临床意义。这项策略也体现在财务表现上。 DiaSorin公司于2025年3月发布的2024财年财务报告显示，其免疫诊断药物销售额（不包括与COVID-19相关的项目）同比增长9%，并指出其专业检测项目的扩展是关键因素。

同时，市场正透过併购进行策略重组，旨在提高营运效率并整合产品系列。为了解决医疗服务分散的问题，领先的诊断公司正在建立诊断生态系统，将照护现场能力与核心检查室基础设施结合。这些併购使公司能够实现显着的成本协同效应，并透过简化生产流程来抵消高额的资本支出。 QuidelOrtho 于 2025 年 8 月发布的「2025 财年第二季财务业绩」凸显了这项以效率为导向的倡议所取得的成功，该业绩报告显示，公司实现了 1 亿美元的年度成本节约，验证了近期整合倡议的有效性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球化学冷光免疫检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（设备{自动化、半自动化}、耗材、软体和服务）
  • 依样本类型（血液、尿液、唾液、其他）
  • 依应用领域（治疗药物监测、肿瘤学、心臟病学、内分泌学、感染疾病、自体免疫疾病、其他）
  • 按最终用户（医院、临床检查室、製药和生物技术公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美化学冷光免疫检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲化学冷光免疫检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区化学冷光免疫检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲化学冷光免疫检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲化学冷光免疫检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球化学冷光免疫检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories Inc.
• Beckman Coulter, Inc
• DiaSorin SpA
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• QuidelOrtho Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Chemiluminescence Immunoassay Market is projected to expand from USD 12.63 Billion in 2025 to USD 16.94 Billion by 2031, achieving a compound annual growth rate of 5.02%. Chemiluminescence Immunoassay (CLIA) serves as a vital diagnostic technique that utilizes chemical reactions to emit light, allowing for the precise quantification of antigens and antibodies in clinical samples. This market growth is fundamentally propelled by the rising global prevalence of chronic and infectious diseases, which drives the need for accurate, high-throughput testing in laboratories. The scale of this demand is highlighted by the MedTech Europe 2024 estimate, which valued the European medical technology market at approximately €170 billion, with in vitro diagnostics representing the largest segment.

However, the market's expansion faces significant hurdles due to the substantial capital investment necessary for automated analyzer platforms. The high acquisition costs of these instruments, along with ongoing expenses for reagents and the need for specialized personnel, create a formidable financial barrier for smaller healthcare facilities and laboratories in resource-limited areas. Consequently, these economic constraints act as a primary impediment, potentially slowing the widespread adoption of this advanced diagnostic technology.

Market Driver

The increasing global burden of chronic and infectious diseases serves as a primary catalyst for the Global Chemiluminescence Immunoassay Market. Clinical laboratories increasingly rely on CLIA due to its superior sensitivity and broad dynamic range compared to traditional methods. In oncology, precise biomarker detection is essential for early diagnosis; the American Cancer Society's "Cancer Facts & Figures 2025" projects 2,041,910 new cancer cases in the United States in 2025, generating immense demand for immunoassay testing. Similarly, high-sensitivity diagnostic tools are crucial for managing infectious diseases, where early detection is key to improving patient outcomes, further solidifying the technology's role in healthcare.

Simultaneously, technological progress in automated, high-throughput CLIA platforms is accelerating market growth by addressing operational challenges in modern laboratories. Diagnostic centers are shifting from manual ELISA methods to fully automated systems to handle rising testing volumes with faster turnaround times and reduced errors. This trend is evident in industry financials; the Roche Annual Report 2024 noted Diagnostics Division sales of CHF 14.3 billion, driven by immunodiagnostic demand. Furthermore, Abbott's "Fourth Quarter and Full-Year 2024 Results" from January 2025 showed a 4.3 percent rise in global Diagnostics sales excluding COVID-19, highlighting the sustained uptake of core diagnostic technologies.

Market Challenge

The significant capital required for automated chemiluminescence immunoassay (CLIA) analyzers acts as a major restraint on market growth. Smaller laboratories and healthcare facilities in resource-limited settings often lack the funds to cover the high upfront acquisition costs of these sophisticated instruments. Furthermore, recurring operational expenses, such as proprietary reagents and specialized maintenance, place additional strain on limited budgets. Consequently, many institutions remain reliant on lower-cost methods like ELISA, which restricts the broader adoption of CLIA technology and directly hinders market expansion.

These financial constraints are clearly reflected in industry spending patterns, which reveal limited resources for diagnostic departments. According to MedTech Europe, expenditure on in vitro diagnostics accounted for approximately 0.6% of total healthcare spending in 2024. This statistic underscores the disproportionately low funding allocated to the diagnostics sector relative to overall healthcare expenditure. Such restricted financial allocation limits the purchasing power of laboratories, rendering the procurement of expensive automated CLIA platforms financially unviable for a significant portion of the potential customer base.

Market Trends

The increased application of novel biomarkers for early detection is fundamentally reshaping the market, prompting clinical laboratories to shift from routine screening to high-value specialty testing. This trend involves the rapid adoption of advanced chemiluminescence assays for complex conditions like autoimmunity, endocrinology, and latent infectious diseases, which offer superior specificity compared to traditional methods. Manufacturers are aggressively broadening their test menus to include these niche biomarkers, thereby securing higher reimbursement rates and clinical relevance. This strategy is reflected financially; DiaSorin's "FY 2024 Results" in March 2025 reported a 9% year-over-year increase in ex-COVID immunodiagnostic revenues, explicitly attributed to the expansion of its specialty test menu.

Simultaneously, the market is undergoing strategic consolidation through mergers and acquisitions aimed at enhancing operational efficiency and portfolio integration. Major diagnostic players are combining point-of-care capabilities with core laboratory infrastructure to build unified diagnostic ecosystems that address fragmented healthcare delivery. These mergers enable companies to realize significant cost synergies and streamline manufacturing to offset high capital equipment costs. The success of this focus on efficiency is visible in QuidelOrtho's "Second Quarter 2025 Results" from August 2025, which announced the realization of $100 million in annualized cost savings, validating the benefits of recent integration initiatives.

Key Market Players

• Abbott Laboratories Inc.
• Beckman Coulter, Inc
• DiaSorin S.p.A
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• QuidelOrtho Corporation

Report Scope

In this report, the Global Chemiluminescence Immunoassay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemiluminescence Immunoassay Market, By Product

• Instruments {Automated, Semi-automated}
• Consumables
• Software & Services

Chemiluminescence Immunoassay Market, By Sample Type

• Blood
• Urine
• Saliva
• Other

Chemiluminescence Immunoassay Market, By Application

• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease
• Autoimmune Disease
• Other

Chemiluminescence Immunoassay Market, By End User

• Hospitals
• Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Other

Chemiluminescence Immunoassay Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemiluminescence Immunoassay Market.

Available Customizations:

Global Chemiluminescence Immunoassay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemiluminescence Immunoassay Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments {Automated, Semi-automated}, Consumables, Software & Services)
  • 5.2.2. By Sample Type (Blood, Urine, Saliva, Other)
  • 5.2.3. By Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, Other)
  • 5.2.4. By End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Chemiluminescence Immunoassay Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Sample Type
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemiluminescence Immunoassay Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Chemiluminescence Immunoassay Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Chemiluminescence Immunoassay Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Chemiluminescence Immunoassay Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Sample Type
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemiluminescence Immunoassay Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Chemiluminescence Immunoassay Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Chemiluminescence Immunoassay Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Chemiluminescence Immunoassay Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Chemiluminescence Immunoassay Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Chemiluminescence Immunoassay Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Sample Type
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Chemiluminescence Immunoassay Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Chemiluminescence Immunoassay Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Chemiluminescence Immunoassay Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Chemiluminescence Immunoassay Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Chemiluminescence Immunoassay Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Chemiluminescence Immunoassay Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Sample Type
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Chemiluminescence Immunoassay Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Chemiluminescence Immunoassay Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Chemiluminescence Immunoassay Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Chemiluminescence Immunoassay Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Sample Type
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Chemiluminescence Immunoassay Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Chemiluminescence Immunoassay Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Chemiluminescence Immunoassay Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Chemiluminescence Immunoassay Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Beckman Coulter, Inc
• 15.3. DiaSorin S.p.A
• 15.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Siemens Healthineers AG
• 15.7. QuidelOrtho Corporation

16. Strategic Recommendations

17. About Us & Disclaimer